elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Papers
Communities
Lab
Pricing
Log in
Sign up
Home
/
Subjects
/
Natalizumab
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Natalizumab
RIS
0.001
(Research Intensity Score)
Papers
53
Top papers
Five-Year Safety and Efficacy Outcomes with Ofatumumab in Patients with Relapsing Multiple Sclerosis
2025 · 15 citations
Real‐World Effectiveness of Initial Disease‐Modifying Therapies in Pediatric Multiple Sclerosis
2020 · 118 citations
Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis
2018 · 215 citations
Effectiveness of Disease-Modifying Therapies in Patients With Late-Onset Relapsing-Remitting Multiple Sclerosis
2025 · 8 citations
De‐Escalation of Disease‐Modifying Therapy in Multiple Sclerosis—A Danish Nationwide Cohort Study
2025 · 10 citations
Real-world effectiveness and safety of ofatumumab in relapsing-remitting multiple sclerosis: Insights from naïve and switch patients
2025 · 7 citations
A review of multiple sclerosis: From pathophysiology to latest therapeutic advances
2025 · 10 citations
Twenty years of natalizumab in multiple sclerosis: lessons learned and future outlook
2025 · 9 citations
Reconstitution of CXCR3 + CCR6 + Th17.1‐Like T Cells in Response to Ofatumumab Therapy in Patients With Multiple Sclerosis
2025 · 7 citations
Newest papers
Maternal and neonatal outcomes following natalizumab use during pregnancy in women with multiple sclerosis: A multicenter observational study
2026 · 1 citations
Lifestyle Modification Rehabilitation and Pharmacotherapy in Multiple Sclerosis
2026
Possible Contribution of Multiple Sclerosis Pathology to Treatment‐Resistant Schizophrenia: A Case Study
2026
Predictors of Multiple Sclerosis After Clinically Isolated Syndrome: A Systematic Review and Meta‐Analysis
2026
Biological and clinical stability after switching from intravenous to subcutaneous natalizumab in RRMS under standard and extended dosing
2026
Subcutaneous natalizumab administration in relapsing–remitting multiple sclerosis: results of EASIER 2 study
2026
Highly active multiple sclerosis - An important, yet inaccurate concept
2026 · 1 citations
Five-Year Safety and Efficacy Outcomes with Ofatumumab in Patients with Relapsing Multiple Sclerosis
2025 · 15 citations
Effectiveness of Disease-Modifying Therapies in Patients With Late-Onset Relapsing-Remitting Multiple Sclerosis
2025 · 8 citations
Browse all papers →
Natalizumab's history
Research intensity over time
Yearly
Personal members see monthly resolution →
Data temporarily unavailable — please try again shortly.
Close ✕
Natalizumab's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link